Topics:
Head and Neck Cancers • Medical Oncology
Would you recommend adding Debio 1143 to high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck?
Based on the results of the phase 2GORTEC study reference; Sun et al., PMID 32758455.
Answer from: Medical Oncologist at Academic Institution
At this point, I will still refer LAHNSCC patients to the phase-3 clinical trial randomizing patients to placebo vs Debio-1143.
Sign in or Register to read more